Related Experiment Videos
Evaluation of in vitro chemosensitivity using human lung cancer cell lines
1Minneapolis VA Medical Center Department of Medicine, USA.
Abstract:
The use of well-characterized human lung cancer cell lines has allowed for new opportunities in preclinical and clinical drug evaluation. Development of semiautomated tests of in vitro cytotoxicity such as the MTT assay, which utilizes the formazan salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), has allowed for preclinical evaluation of novel chemotherapeutic agents and drug combinations. In addition, techniques such as this make possible the testing of sufficient data sets to allow determination of true biochemical drug synergy. Assessment of drug combinations which possess in vitro synergy or supraadditive effects can suggest chemotherapeutic regimens for further clinical testing. Using the MTT assay in conjunction with isobolographic analysis, it is possible to test commonly used regimens which are based on presumed or apparent in vivo drug synergy, such as the combination of etoposide and cis-platinum. This frequently prescribed combination was found to lack in vitro biochemical synergy when tested with human lung cancer cell lines, indicating that the observed clinical benefits of this drug combination may be due to factors in the tumor microenvironment, drug metabolism, or non-overlapping toxicities. Finally, although it remains to be determined if a significant role for in vitro drug testing will be found in direct clinical applications, preclinical drug evaluation during the drug development process using cultured tumor cell lines may ultimately allow for disease or patient specific therapies for testing.
Insights
Preclinical drug testing using the MTT assay on lung cancer cell lines revealed no synergy for etoposide and cis-platinum combinations. Clinical benefits may stem from tumor microenvironment or metabolism, not direct drug synergy.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Well-characterized human lung cancer cell lines are crucial for preclinical and clinical drug evaluation.
- Semiautomated in vitro cytotoxicity assays, like the MTT assay, enable efficient preclinical testing of novel chemotherapeutic agents and combinations.
- These methods facilitate the determination of true biochemical drug synergy and suggest effective chemotherapeutic regimens for clinical trials.
Purpose of the Study:
- To evaluate the in vitro biochemical synergy of commonly used drug combinations, such as etoposide and cis-platinum, in human lung cancer cell lines.
- To assess the utility of the MTT assay combined with isobolographic analysis for determining drug synergy.
- To explore potential reasons for clinical benefits of drug combinations that lack in vitro synergy.
Main Methods:
- Utilized the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for in vitro cytotoxicity testing.
- Employed isobolographic analysis in conjunction with the MTT assay to assess drug synergy.
- Tested the combination of etoposide and cis-platinum on human lung cancer cell lines.
Main Results:
- The combination of etoposide and cis-platinum demonstrated a lack of in vitro biochemical synergy in tested human lung cancer cell lines.
- The MTT assay and isobolographic analysis provided a robust method for assessing drug synergy.
- Observed clinical benefits of the etoposide and cis-platinum combination may be attributed to factors beyond direct in vitro synergy.
Conclusions:
- The etoposide and cis-platinum combination, despite clinical use, does not exhibit in vitro biochemical synergy in lung cancer cell lines.
- Clinical efficacy of drug combinations may be influenced by the tumor microenvironment, drug metabolism, or non-overlapping toxicities.
- In vitro drug testing using cell lines holds potential for developing personalized therapies, though direct clinical applications require further investigation.